Cargando…

Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation

Elevated intratumoral interstitial fluid pressure (IFP) and tumour hypoxia are independent predictive factors for poor survival and poor treatment response in cancer patients. However, the relationship between IFP and tumour hypoxia has not yet been clearly established. Preclinical studies have show...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vlahovic, G, Rabbani, Z N, Herndon, J E, Dewhirst, M W, Vujaskovic, Z
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360712/ https://www.ncbi.nlm.nih.gov/pubmed/17003785 http://dx.doi.org/10.1038/sj.bjc.6603366

Ejemplares similares

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts
por: Vlahovic, G, et al.
Publicado: (2007)

Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
por: Hardee, M E, et al.
Publicado: (2005)

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
por: Stish, B J, et al.
Publicado: (2009)

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
por: Widmer, N, et al.
Publicado: (2008)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells
por: Wang, J, et al.
Publicado: (2012)

Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response
por: Venkatasubramanian, R, et al.
Publicado: (2010)

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression
por: Jonckheere, N, et al.
Publicado: (2009)

The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008)

Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells
por: Timoshenko, A V, et al.
Publicado: (2007)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine
por: Dudley, A C, et al.
Publicado: (2008)

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines
por: Uziel, O, et al.
Publicado: (2005)

Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study
por: Klawitter, J, et al.
Publicado: (2009)

microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome
por: Akçakaya, P, et al.
Publicado: (2014)

Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells
por: Amit-Vazina, M, et al.
Publicado: (2005)

Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer
por: Duivenvoorden, W C M, et al.
Publicado: (2007)

Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression
por: Yamana, K, et al.
Publicado: (2005)

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
por: Schiffmann, L M, et al.
Publicado: (2017)

Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition
por: Duran, George E, et al.
Publicado: (2017)

TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells
por: Cantarella, G, et al.
Publicado: (2006)

VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma
por: Beckermann, B M, et al.
Publicado: (2008)

Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo
por: Nielsen, T O, et al.
Publicado: (2013)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
por: Dean, E J, et al.
Publicado: (2010)

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma
por: Gammons, M V, et al.
Publicado: (2014)

Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma
por: Arrieta, O, et al.
Publicado: (2005)

COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer
por: Timoshenko, A V, et al.
Publicado: (2006)

Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas
por: Yoon, C, et al.
Publicado: (2015)

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
por: Wentink, Madelon Q, et al.
Publicado: (2016)

hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines
por: Masi, A, et al.
Publicado: (2005)

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK
por: Storozhuk, Y, et al.
Publicado: (2013)

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2011)

NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines
por: Yang, Y, et al.
Publicado: (2006)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer
por: Lin, H-J, et al.
Publicado: (2005)

Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours
por: Coutelle, O, et al.
Publicado: (2015)

Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling
por: Baker, Lauren CJ, et al.
Publicado: (2016)

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
por: Orlandi, P, et al.
Publicado: (2013)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_stnta1sqh0a3usv3u84upuv6qv